Last reviewed · How we verify
TLK286 in Combination with Carboplatin
TLK286 in Combination with Carboplatin is a Histone deacetylase inhibitor Small molecule drug developed by Telik. It is currently in Phase 3 development for Metastatic non-small cell lung cancer.
TLK286 is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the inhibition of cancer cell growth and induction of apoptosis.
TLK286 is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the inhibition of cancer cell growth and induction of apoptosis. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | TLK286 in Combination with Carboplatin |
|---|---|
| Sponsor | Telik |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Histone deacetylases are enzymes that remove acetyl groups from histones, leading to chromatin compaction and reduced gene expression. By inhibiting these enzymes, TLK286 promotes a more open chromatin structure, allowing for increased gene expression and ultimately leading to the inhibition of cancer cell growth and induction of apoptosis.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Anorexia
- Weight loss
Key clinical trials
- Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer (PHASE3)
- TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TLK286 in Combination with Carboplatin CI brief — competitive landscape report
- TLK286 in Combination with Carboplatin updates RSS · CI watch RSS
- Telik portfolio CI
Frequently asked questions about TLK286 in Combination with Carboplatin
What is TLK286 in Combination with Carboplatin?
How does TLK286 in Combination with Carboplatin work?
What is TLK286 in Combination with Carboplatin used for?
Who makes TLK286 in Combination with Carboplatin?
What drug class is TLK286 in Combination with Carboplatin in?
What development phase is TLK286 in Combination with Carboplatin in?
What are the side effects of TLK286 in Combination with Carboplatin?
What does TLK286 in Combination with Carboplatin target?
Related
- Drug class: All Histone deacetylase inhibitor drugs
- Target: All drugs targeting Histone deacetylase
- Manufacturer: Telik — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer
- Compare: TLK286 in Combination with Carboplatin vs similar drugs
- Pricing: TLK286 in Combination with Carboplatin cost, discount & access